Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-low Breast Cancer × RC48 antibody × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Ovarian Neoplasms 1 Head and Neck Neoplasms 1 HER2-low Breast Cancer 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

eribulin 1 disitamab vedotin 1 RC48 antibody 1 Paclitaxel 1 Gemcitabine 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡